Impact – AML
General Aspects
Impact-AML [Pragmatic clinical trials to optimise treatments for patients with refractory cancers] is a project funded by the European Commission under the Horizon Europe Mission Cancer with a total budget of €5.988.402,50. The project, coordinated by the Institute for Treatment and Research Istituto Romagnolo per lo Studio Dei Tumori “Dino Amadori“, is focused on Acute Myeloid Leukemia, a high-impact disease in which no standard of care exists, and where there is an urgent need for new evidence on possible therapies.
Project Activities
The project combines the powerful tools of clinical studies with personalized medicine to create an inclusive regulatory framework for patients with relapsed or refractory acute myeloid leukemia in multicenter and multinational clinical trials. cohorts. Thereafter, a prospective randomized pragmatic clinical trial (RPCT) will be conducted to compare the classical “high intensity” rescue chemotherapy with biology-driven and “low intensity” rescue to obtain “real world” data on the benefit of one of the two different strategies in term of survival, also considering patients and caregivers preferences, patient-reported outcomes (PRO), accessibility, affordability, and social cost.
TLS will be responsible for leading the Work Package on dissemination, communication, and valorisation of research results, as well as for managing the engagement of European policy makers.
Website: impactaml.eu